FormsNet3 - Blank Form


 
 
Sequence Number    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number:    

 
 
CIBMTR Recipient ID:    

 
 
Today's Date: __ __ __ __ - __ __- __ __  

 
 
Date of HSCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HSCT type (check all that apply): 

 
  

gfedcb
Autologous

 
 

  
gfedcb

Allogeneic, unrelated

 
 

  
gfedcb

Allogeneic, related

 
 

  
gfedcb

Syngeneic (identical twin)

 

Product type (check all that apply): 

 
  

gfedcb
Marrow

 
 

  
gfedcb

PBSC

 
 

  
gfedcb

Cord blood

 
 

  
gfedcb

Other product

 
 
Specify:    

 
 

Visit:

  
 nmlkji

100 day  
 nmlkji

6 months  
 nmlkji

1 year  
 nmlkji

2 years  
 nmlkji

> 2 years,  

 
 
Specify:    

 
1  Compared to the disease status prior to the preparative regimen, what was the best response to HSCT since the date of the last report? (Include response to any post-HSCT 

treatment planned as of Day 0.) 

    
 nmlkji

continued complete response (CCR) - continued absence of all disease after a complete response to a previous line of therapy  

 nmlkji
complete response (CR)- absence of clincally detectable disease including normal HCG and AFP and normalization of previously abnormal radiographic studies for at least 

one month  

 nmlkji
partial response (PR) - >= 50% reduction in the sum of the perpendicular diameters of measurable lesions for >= 1 month and/or >= 50% reduction in tumor markers  

 nmlkji
stable disease (SD) - tumor regression not fulfilling the requirement for partial response or tumor progression < 25% increase in the bidimensionally measurable tumor 

parameters  

 nmlkji
no response (NR) - <=50% reduction in disease or tumor markers  

 nmlkji
progressive disease (PD) - new lesions that prove to be viable cancer and/or rise in the pre-treatment tumor markers and/or > 25% increase in measurable lesions that are 

related to progressive viable cancer  

 nmlkji
markers elevated (ME) - no measurable disease, but tumor markers elevated  

 nmlkji
not evaluable, toxic death (NETD)  

 
 
2    

gfedcb
date of best response was previously reported

 
 
Date the best response first began: __ __ __ __ - __ __- __ __  

 
 

3  Was the response documented surgically?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

4  Has the disease relapsed or progressed since the date of the last report?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  Key Fields 

Disease Assessment at the Time of Best Response to HSCT Questions: 1 - 3

  Relapse or Progression Post-HSCT Questions: 4 - 18

Form 2122 R2.0: Testicular/Germ Cell Cancer Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2122 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 5



 
 
5    

gfedcb
Date of progression/relapse unknown

 
 
Date of progression / relapse: __ __ __ __ - __ __- __ __  

 
 

6  Allogeneic HSCTs only: Was there subsequent disease stability or regression without further therapy (so-called graft-versus-tumor effect)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
7  Did this change in disease status qualify as a partial response or better if compared to a post-HSCT imaging study?

    (Partial response is defined as >= 50% reduction in the sum of the perpendicular diameters of measurable leasions for >= 1 month and/or >=50% reduction in tumor 
markers.)   

 nmlkji
yes  

 nmlkji
no  

 
 
8    

gfedcb
Date unknown

 
 
Date of response: __ __ __ __ - __ __- __ __  

 

Specify site(s) of disease progression / recurrence: 
 

9  Central nervous system

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

10  Liver-parenchymal

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

11  Lung

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

12  Lymph nodes - distant

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

13  Lymph nodes - regional

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

14  Pelvis

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

15  Pleura

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

16  Tumor markers (AFP, HCG, LDH)

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

17  Other site:

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
18  Specify site:    

 
 

19  Was planned treatment given per protocol since the date of the last report? (Include any maintenance therapy, but exclude any treatment for relapse / progressive disease.)

    
 nmlkji

yes  
 nmlkji

no  

 
 

20  Was surgical resection performed for persistent radiographic abnormalities?

    
 nmlkji

yes  
 nmlkji

no  

 
 
21  Specify date of surgery: __ __ __ __ - __ __- __ __  

  Post-HSCT Planned Treatment for Testicular Cancer Questions: 19 - 57

Form 2122 R2.0: Testicular/Germ Cell Cancer Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2122 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 5



 
 

22  Specify type of surgery:

    
 nmlkji

biopsy only (not debulking)  

 nmlkji
debulking  

 nmlkji
orchioectomy only  

 nmlkji
removal of extra-abdominal metastatic lesion  

 nmlkji
unilateral retroperitoneal lymph node dissection and orchiectomy  

 nmlkji
other type of surgery, specify  

 
 
23  Specify surgery:    

 
 

24  Was the extent of the resection confirmed radiographically?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

25  Was any persistent, viable tumor detected?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

26  Was radiation therapy given?

    
 nmlkji

yes  
 nmlkji

no  

 
 
27  Specify date radiation started: __ __ __ __ - __ __- __ __  

 
 
28  Specify date radiation stopped: __ __ __ __ - __ __- __ __  

 

Specify the radiation field(s): 
 

29  Pelvis

    
 nmlkji

yes  
 nmlkji

no  

 
 
30  Total dose:    cGy (rads) 

 
 

31  Total abdomen

    
 nmlkji

yes  
 nmlkji

no  

 
 
32  Total dose:    cGy (rads) 

 
 

33  Other site:

    
 nmlkji

yes  
 nmlkji

no  

 
 
34  Specify field:    

 
 
35  Total dose:    cGy (rads) 

 
 

36  Was chemotherapy / immunotherapy given?

    
 nmlkji

yes  
 nmlkji

no  

 
 
37  Specify date therapy started: __ __ __ __ - __ __- __ __  

 
 
38  Specify date therapy stopped: __ __ __ __ - __ __- __ __  

 

Specify systemic treatment(s): 
 

39  aldesleukin (interleukin-2)

    
 nmlkji

yes  
 nmlkji

no  

 
 

40  altretamine (Hexalen)

    
 nmlkji

yes  
 nmlkji

no  

 
 

41  bleomycin (BLM, Blenoxane)

    
 nmlkji

yes  
 nmlkji

no  

 
 

42  carboplatin (Paraplatin)

    
 nmlkji

yes  
 nmlkji

no  

Form 2122 R2.0: Testicular/Germ Cell Cancer Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2122 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 5



 
 

43  cisplatin (CDDP, Platinol)

    
 nmlkji

yes  
 nmlkji

no  

 
 

44  cyclophosphamide (CTX)

    
 nmlkji

yes  
 nmlkji

no  

 
 

45  dactinomycin (Cosmegen)

    
 nmlkji

yes  
 nmlkji

no  

 
 

46  Doxorubicin (Adriamycin)

    
 nmlkji

yes  
 nmlkji

no  

 
 

47  Doxorubicin liposomal (Doxil)

    
 nmlkji

yes  
 nmlkji

no  

 
 

48  Etoposide (VP-16, VePesid)

    
 nmlkji

yes  
 nmlkji

no  

 
 

49  Gemcitabine (Gemzar)

    
 nmlkji

yes  
 nmlkji

no  

 
 

50  Ifosfamide (Ifex)

    
 nmlkji

yes  
 nmlkji

no  

 
 

51  Mitoxantrone (Novantrone)

    
 nmlkji

yes  
 nmlkji

no  

 
 

52  methotrexate (MTX, Folex)

    
 nmlkji

yes  
 nmlkji

no  

 
 

53  paclitaxel (Taxol)

    
 nmlkji

yes  
 nmlkji

no  

 
 

54  thiotepa (Thioplex)

    
 nmlkji

yes  
 nmlkji

no  

 
 

55  vinblastine (Velban, VLB)

    
 nmlkji

yes  
 nmlkji

no  

 
 

56  other therapy

    
 nmlkji

yes  
 nmlkji

no  

 
 
57  Specify treatment:    

 

Specify the results of any imaging studies performed for the following disease sites since the date of the last report: 
 

58  Abdomen - CT

    
 nmlkji

disease present  
 nmlkji

disease absent  
 nmlkji

Not tested  

 
 

59  Bone - bone scan

    
 nmlkji

disease present  
 nmlkji

disease absent  
 nmlkji

Not tested  

 
 

60  Bone - CT

    
 nmlkji

disease present  
 nmlkji

disease absent  
 nmlkji

Not tested  

 
 

61  Bone - MRI

    
 nmlkji

disease present  
 nmlkji

disease absent  
 nmlkji

Not tested  

  Most Recent Laboratory Studies Post-HSCT Questions: 58 - 77

Form 2122 R2.0: Testicular/Germ Cell Cancer Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2122 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 5



 
 

62  Bone - x-ray

    
 nmlkji

disease present  
 nmlkji

disease absent  
 nmlkji

Not tested  

 
 

63  Chest - CT

    
 nmlkji

disease present  
 nmlkji

disease absent  
 nmlkji

Not tested  

 
 

64  Chest - x-ray

    
 nmlkji

disease present  
 nmlkji

disease absent  
 nmlkji

Not tested  

 
 

65  Head - CT

    
 nmlkji

disease present  
 nmlkji

disease absent  
 nmlkji

Not tested  

 
 

66  Head - MRI

    
 nmlkji

disease present  
 nmlkji

disease absent  
 nmlkji

Not tested  

 
 

67  Pelvis - CT

    
 nmlkji

disease present  
 nmlkji

disease absent  
 nmlkji

Not tested  

 
 

68  PET scan

    
 nmlkji

disease present  
 nmlkji

disease absent  
 nmlkji

Not tested  

 

Specify the following tumor markers determined since the date of the last report: 
 

69  Serum alpha-fetoprotein (AFP):

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
70     ng/mL 

 
 

71  Serum beta-HCG (BHCG):

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
72     IU/L 

 
 

73  LDH:

    
 nmlkji

Known  
 nmlkji

Not known  

  
 
74     

 
Specify units

 nmlkji
U/L  

 nmlkji
µkat/L  

 
 

75  Other tumor marker?

    
 nmlkji

yes  
 nmlkji

no  

 
 
76  Specify tumor marker:    

 
 
77  Specify value:    

 
 

78  What is the current status of testicular cancer at the time of this report, or at the time of death?

    
 nmlkji

Complete response  

 nmlkji
not in complete response  

 
 
79  Date the current disease status was established in this reporting period: __ __ __ __ - __ __- __ __  

  
 
First Name:    

 
Last Name:    

  
 
Phone number:    

 
Fax number:    

 
 
E-mail address:    

  Disease Status at the Time of Assessment for this Reporting Period Questions: 78 - 79

Form 2122 R2.0: Testicular/Germ Cell Cancer Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2122 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 5 / 5